Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Bjorn Dahlback"'
Publikováno v:
Critical Reviews in Clinical Laboratory Sciences. 42:249-277
There have been major advances in our understanding of thrombosis and antithrombotic drugs. This review focuses on the molecular aspects of thrombus formation and antithrombotic therapy. Molecules involved in arterial thrombosis are derived from infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b716816b5a93dd2b09b2b5df205443
https://doi.org/10.1080/10408360590951171
https://doi.org/10.1080/10408360590951171
Autor:
Bjorn Dahlback
Publikováno v:
The Lancet. 355:1627-1632
Under normal circumstances, the coagulation system is balanced in favour of anticoagulation. Thrombin is the key effector enzyme of the clotting cascade. Antagonists of vitamin K inhibit a vitamin-K-dependent post-translational modification of severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad894d9c5bbafe4ffc39e771a3e02a6d
https://doi.org/10.1016/s0140-6736(00)02225-x
https://doi.org/10.1016/s0140-6736(00)02225-x
Autor:
Bjorn Dahlback
Publikováno v:
Europe PubMed Central
Inherited resistance to activated protein C (APC) is the most common genetic risk factor of venous thrombosis. It is caused by a single point mutation in the factor (F)V gene which predicts replacement of Arg506 with a Gln (FVR506Q, FV: Q506 or FV Le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e94a8a93cab3fe70706c4192503e096
https://doi.org/10.1055/s-2007-994931
https://doi.org/10.1055/s-2007-994931
Autor:
Bjorn Dahlback
Publikováno v:
Europe PubMed Central
Genetic risk factors are important in the pathogenesis of venous thrombosis, as demonstrated by the familial clustering of the disease. However, well defined genetic defects were until recently found in less than 10% of the thrombosis patients. In 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32c1571b163edf9c9fce35621076e8f5
https://doi.org/10.1055/s-0038-1642667
https://doi.org/10.1055/s-0038-1642667
Publikováno v:
Europe PubMed Central
C4b binding protein (C4BP) regulates the complement system. It also interacts with anticoagulant protein S and with serum amyloid P component. Human C4BP is composed of seven identical 70-kDa alpha-chains and one 45-kDa beta-chain. The binding site f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21fb62be21730f8da31d2eee9789623
https://doi.org/10.4049/jimmunol.153.9.4190
https://doi.org/10.4049/jimmunol.153.9.4190
Publikováno v:
BJOG : an international journal of obstetrics and gynaecology. 110(5)
Recent studies suggest an increased prevalence of obstetric complications in female carriers of hereditary or acquired thrombophilias. The aim of the study was to determine if carriership of the factor V (FV) Leiden mutation (activated protein C [APC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f02157dff6a1cc3866647a5310bb78c
https://pubmed.ncbi.nlm.nih.gov/14687065
https://pubmed.ncbi.nlm.nih.gov/14687065
Autor:
Eric Manderstedt, Christina Lind‐Halldén, Christer Halldén, Johan Elf, Peter J. Svensson, Björn Dahlbäck, Gunnar Engström, Olle Melander, Aris Baras, Luca A. Lotta, Bengt Zöller
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 4 (2022)
Background Five classic thrombophilias have been recognized: factor V Leiden (rs6025), the prothrombin G20210A variant (rs1799963), and protein C, protein S, and antithrombin deficiencies. This study aimed to determine the thrombotic risk of classic
Externí odkaz:
https://doaj.org/article/ea61244395784f04806e757e89ec07b6
Publikováno v:
Europe PubMed Central
During the last few years several genetic markers have been discovered that contribute to an increased risk of venous thrombosis. Patients who have several genetic markers are at a considerably higher risk of being affected than patients with only on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bed6a18c29acf697afaea9a923504447
https://pubmed.ncbi.nlm.nih.gov/11192769
https://pubmed.ncbi.nlm.nih.gov/11192769
Publikováno v:
Europe PubMed Central
Activated factor V (FVa) serves as a cofactor to activated factor X in the prothrombinase complex. FVa is homologous to activated factor VIII (FVIIIa), the light chains of both proteins being formed by similar domains (A3-C1-C2). Interaction of FVa a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2dd51bb8df39dc9c1fc759b523ee20cf
https://pubmed.ncbi.nlm.nih.gov/10691103
https://pubmed.ncbi.nlm.nih.gov/10691103
Publikováno v:
Europe PubMed Central
Activated protein C (APC) resistance, due to a point mutation in the factor V gene (FV:Q506), is a major risk factor for venous thromboembolism. To determine the prevalence of APC resistance in a large series of pregnant women, and to elucidate its o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ed6b5545bbb1f0fc026ab51344708433
https://pubmed.ncbi.nlm.nih.gov/10235434
https://pubmed.ncbi.nlm.nih.gov/10235434